Latanoprost-PPDS
DrugControl of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
NCT Number: NCT00650702
The purpose of this study is to determine if the Punctum Plug Delivery System (PPDS) is safe and effective in controlling intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Artesia, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
Time frame: 12 Weeks
Mati Therapeutics Inc.
Industry
A Phase II, Randomized, Masked, Parallel-Group Study of Safety and Preliminary Efficacy of the Punctum Plug Delivery System in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Acronym: CORE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02710916
Eye Diseases, Glaucoma
Bordeaux, Aquitaine, France
View Trial DetailsNCT06689696
Eye Diseases, GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Fullerton, California, United States
View Trial DetailsNCT06394973
Eye Diseases, Glaucoma
Glendale, Arizona, United States
View Trial DetailsNCT07154797
Cataract, Eye Diseases
Santa Rosa de Copán, Honduras
View Trial Details